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Abstract: Anaemia is the most frequent, though often neglected, comorbidity of inflammatory
bowel disease (IBD). Here we want to briefly present (1) the burden of anaemia in IBD, (2) its
pathophysiology, which mostly arises from bleeding-associated iron deficiency, followed by
(3) diagnostic evaluation of anaemia, (4) a balanced overview of the different modes of iron
replacement therapy, (5) evidence for their therapeutic efficacy and subsequently, (6) an updated
recommendation for the practical management of anaemia in IBD. Following the introduction of
various intravenous iron preparations over the last decade, questions persist about when to use these
preparations as opposed to traditional and other novel oral iron therapeutic agents. At present, oral
iron therapy is generally preferred for patients with quiescent IBD and mild iron-deficiency anaemia.
However, in patients with flaring IBD that hampers intestinal iron absorption and in those with
inadequate responses to or side effects with oral preparations, intravenous iron supplementation
is the therapy of choice, although information on the efficacy of intravenous iron in patients with
active IBD and anaemia is scare. Importantly, anaemia in IBD is often multifactorial and a careful
diagnostic workup is mandatory for optimized treatment. Nevertheless, limited information is
available on optimal therapeutic start and end points for treatment of anaemia. Of note, neither
oral nor intravenous therapies seem to exacerbate the clinical course of IBD. However, additional
prospective studies are still warranted to determine the optimal therapy in complex conditions such
as IBD.
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1. Introduction
Anaemia and iron deficiency are global health issues and a recent analysis estimated that
approximately one-third (i.e., >2.5 billion individuals) of the world’s population is anaemic [1].
Furthermore, it is assumed that more than half the cases of anaemia are caused by an iron-deficient
erythropoiesis [1]. Iron deficiency is therefore considered one of the most prevalent global nutritional
deficiencies [2]. However, there is a huge geographic variation in prevalence due to a range
of sociodemographic factors (i.e., industrialized versus developing countries) [1]. Nevertheless,
in addition to anaemia, iron deficiencies cause decrements in energy metabolism, daily activities,
quality of life, cognitive and sexual function, cardiac performance and work productivity. However,
excess iron can cause cellular oxidative stress and damage by catalysing the formation of toxic radicals
via Fenton chemistry [1–6].
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1.1. Anaemia in Inflammatory Bowel Disease
In inflammatory bowel disease (IBD) [7,8], which shows increasing worldwide incidence and
prevalence rates [9–11] and which affects up to 0.5% of the population in some countries [12], anaemia
is a frequent comorbidity. A recent nationwide Portuguese cross-sectional study of 1287 patients with
either Crohn’s disease (CD) (n = 775) or ulcerative colitis (UC) (n = 512) revealed that flaring disease is
the parameter most consistently related to the presence of anaemia, with no differences between CD and
UC, although anaemia is more frequent among women [13], especially in CD [14]. Further, an analysis
of 171 adult patients with CD showed that iron deficiency was present in 78% with active inflammation
but in only 21% with quiescent disease (p < 0.001) [15]. It was noticed that markers of CD severity, such
as stricturing disease and the need for tumour necrosis factor (TNF) inhibitors and surgery, appeared
to be significantly associated with iron deficiency [15]. Moreover, a 2014 systematic review of tertiary
referral centres showed a prevalence of anaemia in patients with CD of 27% (95% confidence interval
(CI) 19–35%) and in patients with UC of 21% (95% CI 15–27%) [7]. The observed variation mirrored
differences in the study populations (e.g., hospitalized patients versus outpatients) as well as the
applied definition of anaemia in the studies included. Hence iron deficiency deserves attention in IBD,
where the mean prevalence is shown to be 20% among outpatients [16] and 68% among hospitalized
patients [17], exceeding by far the frequencies of other extraintestinal manifestations (e.g., rheumatic,
dermatologic and ophthalmologic) commonly associated with IBD [18,19].
The pathogenesis of anaemia in IBD is multifactorial and results mainly from intestinal blood
loss in inflamed mucosa and impaired dietary iron absorption [20]. The chronic inflammatory state
impairs duodenal iron uptake via induction of hepcidin expression in the liver [21] but inflammatory
cytokines also have a negative impact on the duodenal uptake of nutrients. Moreover, loss of
appetite during flaring disease and a range of other factors such as medications used for IBD
treatment (e.g., proton pump inhibitors, sulfasalazine, methotrexate and thiopurines) also have a
negative effect on iron absorption and erythropoiesis [22,23]. Vitamin deficiencies, concomitant
medical conditions (e.g., renal insufficiency, congestive heart failure, haemolysis, diabetes and innate
hemoglobinopathies) [24,25], inflammatory cytokines and acute-phase reactants during flaring disease
additionally impair iron availability for erythropoiesis and/or aggravate anaemia by other mechanisms.
This blunts the biological response to erythropoietin as well and drives an inflammation-dependent
impairment of erythroid progenitor cell proliferation [26–28]. Additionally, a predisposition to the
development of anaemia may be caused by polymorphisms of iron metabolism genes as well as
hormonal factors [29–31]. In essence, if the absorptive capacity of iron from the diet does not meet the
body’s requirement, iron deficiency develops.
1.2. Anaemia in Other Chronic Diseases
Apart from IBD, anaemia is observed in a number of chronic inflammatory disorders. These
include autoimmune disorders (e.g., rheumatoid arthritis and celiac disease), cancer and infections.
This so-called anaemia of chronic disease (ACD) or anaemia of inflammation is more prevalent in
patients with advanced disease and in those responding poorly to therapy [28].
1.3. General Health Effects of Anaemia
Treatment of iron-deficiency anaemia in IBD is of importance because of the possible consequences
on multiple organs and biological processes. These include cellular dysfunctions comprising
impaired mitochondrial respiratory capacity and metabolic impairments that translate into specific
organ dysfunctions, for example, in the central nervous system (e.g., impaired cognitive function,
fatigue, restless legs syndrome and depression), immune system (e.g., immune cell proliferation and
differentiation and regulation of innate and adaptive immune responses), cardiorespiratory system
(e.g., reduced exercise capacity, exertional dyspnea, tachycardia, palpitations, cardiac hypertrophy,
systolic ejection murmur and risk of cardiac failure), vascular system (e.g., hypothermia and skin
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pallor), genital tract (e.g., loss of libido and menstrual problems) and gastrointestinal tract (e.g.,
anorexia, nausea and motility disorders) [32,33]. Collectively, anaemia has a direct impact on the
quality of life of affected patients [34–37].
The perception that anaemia in IBD needs specific treatment apart from regular control of IBD is
still underdeveloped. Thus anaemia is neither diagnostically worked up nor do the majority of anaemic
patients receive any specific treatment [17], although such an approach is strongly recommended
by expert boards and clinical societies [25,38,39]. At present, a great many physicians are uncertain
about applicable diagnostic procedures and treatment regimens for their patients with IBD and
iron-deficiency anaemia [40]. The aims of this paper therefore are to explore the latest knowledge
concerning the pathophysiology of anaemia, diagnostic evaluations, available iron replacement
methods and evidence of clinical efficacy in order to provide updated recommendations for the
management of iron-deficiency anaemia in IBD.
2. Pathophysiology of Anaemia in IBD
Iron constitutes a key part of haemoglobin in erythrocytes and of myoglobin in muscles, which in
combination contain approximately two-thirds of the total body iron. In addition, iron is crucial to a
wide range of biological processes [41,42]. The average adult harbours more than 3–4 g of iron, which is
balanced between physiologic iron loss and dietary uptake. About 20–25 mg of iron is needed daily for
the synthesis of heme. Thus approximately 1–2 mg originates from dietary intake and the remainder is
acquired by recycling of iron from senescent erythrocytes by macrophages [41,43]. The total loss of
iron averages 1–2 mg/day, mostly through desquamation of intestinal enterocytes or skin, whereas
much higher amounts are lost during menstruation [44,45].
2.1. Structure of Iron
Dietary iron is available in two forms: heme and non-heme-bound iron. Within heme, iron
is complexed as ferrous iron (Fe2+) to the protoporphyrin ring, which is abundant in animal food
products such as meat, poultry and seafood [46]. Most dietary iron is abundant as nonheme iron (Fe3+
or ferric iron) and is present in foods of vegetable origin (e.g., nuts, beans, vegetables and fortified grain
products). Heme iron is assumed to constitute 10–15% of total iron intake in meat-eating populations
but because of its higher bioavailability (estimated absorption rate of 15–35%) than nonheme iron
(5–15%), it accounts for more than 30% of the total absorbed iron [47].
2.2. Iron Homeostasis
Body iron homeostasis is regulated systemically by several mechanisms, among which is the
pivotal interaction of the liver-derived peptide hormone hepcidin with the major cellular iron exporter
ferroportin [48]. Ferroportin is found primarily on intestinal epithelium (mostly in the duodenum),
macrophages and hepatocytes, which constitute the major cellular iron stores. Ferroportin thus
enables the transport of iron from cells into the circulation to maintain adequate systemic iron
levels (Figure 1) [49]. Targeting of ferroportin by hepcidin results in ferroportin internalization,
degradation and blockage of cellular iron egress into the serum, thus resulting in a reduced availability
of iron for erythroid progenitor cells [49]. Synthesis and release of hepcidin and therefore cellular
accumulation of iron and development of a low serum iron concentration, are induced by both
a high concentration of iron in the liver and plasma and by inflammatory cytokines such as IL-1
(IL: interleukin) and IL-6 [50]. In contrast, during states of iron deficiency, hypoxia and anaemia,
the synthesis of hepcidin is blocked in order to increase serum iron levels [29,49,51]. Of note, sexual
hormones, alcohol, hepatic function and hypoxia-derived factor all affect hepcidin expression and
thus the circulating iron levels [41–43]. The efficacy of orally administered iron therapy depends on
circulating hepcidin levels. Thus, high hepcidin concentrations may predict nonresponsiveness to oral
iron therapy [52]. Hepcidin levels may also control the response to intravenous iron administration,
including high-molecular-weight preparations, which are taken up by macrophages and then
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delivered to the circulation via ferroportin-mediated iron export (Figure 1) [2,21,53]. This is in
line with experimental data demonstrating reduced ferroportin expression in the duodenum and
decreased iron absorption in individuals with increased hepcidin levels—primarily as a consequence
of inflammation [21]. The development of inflammatory anaemia is thus characterized by low
circulating iron levels and an iron-restricted erythropoiesis in the presence of high iron stores in
the reticuloendothelial system, reflected by normal or elevated levels of ferritin.
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Between 1 and 2 mg of iron is taken up daily from the diet, which is bala ced by its secretion
mai ly through intestinal and skin epithelial d squamation. Int stinal bleeding in patients with
IBD incr ases iron loss. With th ajority of iron being taken up in the duodenum through heme
and n nheme iron transp rters (elementary iron is reduced to Fe2+ b fore uptake) with animal data
showing some absorption from the large bowel as well [54], the iron enters the epithelial cells. Iron
might be stored in the cells as mucosal ferritin or is exported to the circulation through the transporter,
ferroportin and oxidized to Fe3+. Circulating iron forms complexes with transferrin and is delivered
as transferrin-bound iron to cells and tissues. Most of the iron needed for metabolic purposes and
erythropoiesis (approximately 20–30 mg/day) originates from macrophages that engulf senescent
erythrocytes and reuse iron that is returned to the circulation via ferroportin. During systemic
inflammation and increased levels of inflammation-induced hepatic hepcidin secretion, the iron
transporter ferroportin found in cells of the reticuloendothelial system and in enterocytes is degraded
and cellular iron export is reduced. This results in iron retention in cells of the reticuloendothelial
system and impaired dietary iron absorption, subsequently resulting in low serum iron levels with
all the clinical consequences mentioned in the text. To overcome iron deficiency in patients with
IBD, iron supplementation in the form of oral or intrav nous iron can be applied. Novel approaches
incl de inhibitio of hepcidin itself or its expression. The most important prev ntive intervention for
long-term well-being of the patients, however, is to efficiently treat the underlying condition, in this
case the intestinal inflammatory process. The asterisk indicates points of therapeutic intervention.
2.3. Inflammatory Modulators in Anaemia
Cytokine-driven induction of hepcidin expression and the direct effects of cytokines on iron
trafficking in macrophages and duodenal enterocytes play a decisive role in the development of
ACD) or anaemia of inflammation by retaining iron in the reticuloendothelial system and blocking
iron absorption, causing an iron-limited erythropoiesis [28,55]. Thus, ACD is more prevalent in
patients with advanced disease and in those responding poorly to therapy [28]. In addition, cytokines
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and chemokines further contribute to anaemia by negatively influencing the biological activity of
erythropoietin, by inhibiting the proliferation and differentiation of erythroid progenitor cells and by
reducing the circulatory half-life of erythrocytes [28].
However, patients with flaring IBD experience chronic blood loss due to intestinal mucosal
bleeding, which often causes true iron deficiency in conjunction with inflammatory anaemia (mirrored
by low to normal ferritin levels) [22,56]. Of note, while hepcidin levels are increased in patients with
ACD, concomitant true iron deficiency results in hepcidin suppression [21]. On the one hand, this
is due to the fact that iron deficiency inhibits SMAD-mediated signalling pathways in hepatocytes,
thereby blocking hepcidin expression even in the presence of inflammatory stimuli such as IL-6 [57].
On the other hand, anaemia and hypoxia result in activation of hormones that have a negative
impact on hepcidin formation. These include erythroferrone produced by erythroblasts in response
to erythropoeitic stress [58], as well as other mechanisms, including growth differentiation factor
15 (GDF-15), which is seen mainly in patients with hemoglobinopathies. Further, a hypoxia-driven
blockade of hepcidin formation is induced via platelet-derived growth factor-BB (PDGF-BB) and/or
hypoxia-inducible factors (HIFs) [58–62]. Together these mechanisms result in increased circulating
iron levels via stimulation of iron absorption and redelivery from macrophages. Thus, in the presence of
both inflammation and true iron deficiency due to intestinal bleeding in IBD, circulating hepcidin levels
decrease because anaemia and iron-deficiency regulatory signals dominate over inflammation-driven
hepcidin induction [62,63]. Therefore, truly iron-deficient patients, even in the presence of systemic
inflammation, are able to absorb considerable amounts of iron from the intestine [21,49].
Finally, vitamin deficiencies (e.g., vitamin B12, folic acid and vitamin D) due to either intestinal
inflammation or extensive bowel resection can also contribute to the development of anaemia [22,64],
as do specific medications for the treatment of IBD (as listed earlier).
3. Diagnostic Investigations
According to the World Health Organization (WHO), adult males and females with a blood
haemoglobin concentration below 13 and 12 g/dL, respectively, are considered anaemic (<11 g/dL
during pregnancy) [31]. Thresholds for defining the state of anaemia apart from sex and pregnancy,
however, depend on such factors as age, altitude and ethnicity. The diagnosis of iron deficiency and
anaemia is based on measurements of the blood haemoglobin concentration but some additional
basic analyses are required for a diagnostic workup and for tailoring optimal therapy in patients with
IBD [29,38,65]. During flaring IBD, measurements of iron status may be difficult to interpret because
parameters relating to iron metabolism are influenced by the inflammation per se [66].
3.1. Transferrin and Transferrin Saturation
As a consequence of chronic inflammation, patients with active IBD may show reduced levels
of transferrin, which is contrary to the definition of patients with iron deficiency [67]. Importantly,
patients with inflammatory anaemia with or without true iron deficiency are characterized by reduced
serum iron and a low transferrin saturation (TfS) (i.e., the quotient of iron concentration (µmol/L)
divided by transferrin concentration (mg/dL) in fasting blood samples multiplied by 70.9 and stated
as a percentage) [68]. Accordingly, a number of studies have used TfS as an indicator for low iron
status and for determining appropriate initiation of iron supplementation therapy [37,38,69–71]. A TfS
of 16% is generally used as a threshold when screening for iron deficiency, although a 20% threshold is
often applied in the context of coexisting inflammatory disorders [65].
3.2. Ferritin
Serum ferritin concentration, which generally correlates with body iron stores, is the most
widely used surrogate marker of stored iron and works nicely in patients without any concomitant
inflammatory condition. Circulating ferritin levels, however, are influenced by inflammation;
in fact, several proinflammatory cytokines stimulate ferritin expression, leading to measurements
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in the normal or even elevated range during chronic inflammation, even in the presence of true
iron deficiency [66,72,73]. Thus, in situations of concomitant inflammation, chronic liver disease,
or malignancy, ferritin levels may increase independently of iron status. Thus, independent of
inflammation, a ferritin concentration below 30 µg/L is indicative of true iron deficiency [74,75],
whereas this threshold may be higher in patients with inflammation, although prospective and
interventional studies examining this issue in detail are lacking. In clinical practice, a ferritin level of
up to 100 µg/L in the setting of an inflammatory disease and anaemia may be associated with true iron
deficiency, whereas functional iron deficiency may be present with ferritin levels exceeding 100 µg/L in
such conditions [68]. Currently, no standard clinical tests exist for the assessment of true iron deficiency
in patients with concomitant inflammation and thus a combination of various paraclinical tests is often
required to provide clinical evidence of iron deficiency and to guide therapy [68,76].
3.3. Soluble Transferrin Receptor
Serum-soluble transferrin receptor (sTfR), a proteolytic derivative of the membrane-bound
transferrin receptor, is another marker of iron status. With true iron deficiency, increased synthesis
of transferrin receptors is observed along with a corresponding increase in sTfR levels. Nevertheless,
the sTfR concentration might also rise during disorders associated with increased erythropoiesis,
including chronic lymphatic leukaemia, whereas it can be reduced by the actions of cytokines
during inflammation. Therefore, no consensus currently exists as to a standardized cut-off value
for sTfR [77]. To distinguish between patients with inflammation-driven ACD and patients with ACD
and concomitant true iron deficiency, determination of the ratio between sTfR and the logarithm of
serum ferritin concentration (i.e., the sTfR-F index) has been recommended [78]. A sTfR-F index above
two is indicative of true iron deficiency among ACD patients, whereas a ratio below one is suggestive
of ACD alone without concomitant iron deficiency [68,77].
3.4. Red Cell Indices
Based on erythrocyte analyses of full blood samples from anaemic patients, information
about mean cellular haemoglobin concentration (MCHC, hypochromia) and mean cell volume
(MCV, microcytosis) can be obtained. The values of these indices are decreased by iron deficiency.
In the case of microcytosis in patients with an appropriate ethnic background, haemoglobin
electrophoresis may be considered to rule out hemoglobinopathies such as sickle-cell disease and
thalassemia [77]. Microcytosis or MCHC reductions thus may indicate true iron deficiency in patients
with inflammation-associated ACD because classical ACD is characterized as normochromic and
normocytic [66,67,70,76]. Among patients with chronic kidney disease, measuring the percentage of
circulating hypochromic red cells as a proportion of total red blood cells can indicate the presence
of iron deficiency using a cut-off value of 6% [79]. Unfortunately, freshly drawn blood samples and
specific equipment are required for this analysis [80]. Accordingly, prospective evaluations of this
parameter, as well as of the reticulocyte haemoglobin content in clinical situations, including patients
with anaemia and inflammatory disorders, are scarce [68,81].
3.5. Bone Marrow Analyses
Bone marrow aspiration for diagnosing iron deficiency appears to be the gold standard. This
method is thought to be unaffected by inflammation but it is invasive in nature, uncomfortable for the
patient, expensive and might be affected by concomitant treatment with recombinant erythropoietin.
Thus, bone marrow aspiration should be reserved for specific situations where other techniques are
either unavailable or conflicting [77].
3.6. Hepcidin
Hepcidin has a key regulatory role in iron homeostasis as an inhibitor of cellular iron export [77].
Measurements of hepcidin may be an attractive tool to diagnose true iron deficiency in patients with
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inflammation-driven anaemia because its expression in vivo appears to be more affected by iron
deficiency than by the inflammatory response [62,82]. Recently, commercially available tests have
been introduced into clinical practice [83] but the usefulness of hepcidin determination to correctly
indicate iron deficiency in patients with inflammation needs to be tested prospectively in future studies.
Of note, concomitant pathologies that may contribute to the development and severity of anaemia,
including folic acid, cobalamin, or vitamin D deficiency and haemolysis and erythropoietin deficiency
per se, as well as any renal insufficiency, must be identified and treated properly, if possible.
It is of great importance to establish the presence of true iron-deficiency anaemia in patients to
avoid any unnecessary treatment. The assessment should be guided by predictive serum parameters
such as hepcidin, soluble transferrin receptor and others including red cell indices but no gold standard
is available at present [76,84]. The success of treatment with either oral or intravenous iron is mirrored
by an increase of haemoglobin levels or by increased levels of circulating ferritin.
4. Treatment of Anaemia
The primary treatment of ACD is to cure the underlying pathology or other easily treatable
conditions contributing to anaemia, such as vitamin deficiency, which often leads to improvement in
haemoglobin levels unless other pathophysiologic factors or deficiencies are present [14,25,28,29,33,85].
In cases of severe anaemia (i.e., haemoglobin < 7–8 g/dL) [2,86], especially when it is rapidly
developing, as in association with acute gastrointestinal bleeding, or if the patient suffers from
comorbidities such as coronary heart disease or chronic pulmonary disease, a rapid correction
of haemoglobin levels may be indicated, which can best be achieved with red blood cell
transfusions [25,28,33,87]. However, the use of blood transfusions must be considered carefully because
negative effects are well documented [87,88] and a liberal application of transfusions is associated with
higher mortality in patients with acute gastrointestinal bleeding [89]. Moreover, transfusions have
been associated with an increased risk for nosocomial infections and mortality rates among intensive
care patients [90], as well as a higher frequency of surgical-site infections [91]. Additionally, a risk
of transfusion-related anaphylactic reaction, together with a small but residual risk for transmitting
infectious disease, does exist [92–94].
5. Iron Replacement Formulations
Imbalances of iron homeostasis are the major reason for anaemia in patients with IBD.
The currently available options for iron supplementation to balance iron intake and iron loss consist of
oral and intravenous administration and their pros and cons are listed in Table 1.
Table 1. Main principles of iron supplementation and their pros and cons.
Iron Administration Pros Cons
Oral
Low cost
Convenient
Available over the counter
Efficient when intestinal absorption
is not impaired
Mucosal injury
Alteration of microbiota
Various disorders may impair uptake, e.g.,
celiac disease, ACD *, autoimmune gastritis
High intestinal iron concentrations due to low
bioavailability cause gastrointestinal side
effects (nausea, vomiting, abdominal pain
and constipation) and limit compliance
Intravenous
Fast repletion of iron stores
Safe if formulations with dextran are
avoided
Effective even when intestinal
absorption is impaired
Higher expenses, including need for
administration by a healthcare professional
Potential risk for iron overload that in excess
may contribute to oxidative stress
Potential risk for anaphylactic reactions using
dextran-containing formulations
Hypophosphatemia with some preparations
* Anaemia of chronic disease (ACD).
Nutrients 2018, 10, 82 8 of 25
5.1. Oral Regimen
The bioavailability of “traditional” oral iron preparations is relatively low but nevertheless is
the first-line therapy in iron-deficiency anaemia. Oral iron has a well-established safety profile,
is easy to administer and comes with a generally low cost—with the latter being important in a
pharmaco-economical setting [26]. Oral iron supplements are available as divalent Fe2+ (ferrous) or
trivalent Fe3+ (ferric) salts coupled with sugar complexes or protein succinylate [95,96]. The most
widely used preparations are ferrous sulphate, ferrous gluconate and ferrous fumarate, which
all contain the ferrous form of iron, which has a better bioavailability than ferric-containing
formulations [96]. Prior to absorption by enterocytes in the duodenum, iron is reduced to its ferrous
state (Fe2+)—A process catalysed by membrane-bound ferric reductase. Divalent metal transporter-1
(DMT1) facilitates iron uptake in the acidic environment [97]. Ascorbic acid (or vitamin C) dose
dependently facilitates absorption of oral iron [98] by providing reducing equivalents for ferric
reductase, thus enhancing the reduction of Fe3+ to Fe2+ prior to epithelial uptake [99]. Further,
vitamin C suppresses the negative effects on iron absorption of inhibitors such as phytate and
calcium [47] (Figure 2).
Recently, a study in children has shown that supplementation of vitamin D facilitates increased
haemoglobin levels. Here plasma concentrations of 25-hydroxyvitamin D (25(OH)D) below 30 ng/mL
(i.e., vitamin D deficiency) were associated with increased hepcidin concentrations and reduced
haemoglobin concentrations compared with individuals with plasma 25(OH)D concentrations above
30 ng/mL [100]. Because vitamin D deficiency is frequent in IBD [101] and because vitamin D has been
shown to inhibit hepcidin expression [102] and to possess important immunologic effects of benefit in
the clinical course of patients with IBD [103–105], normalization of vitamin D is important for elevating
the haemoglobin level in these patients. Specifically, vitamin D binds to vitamin D response elements
(VDREs) in the promoter region of hepcidin (hepcidin antimicrobial peptide, HAMP) and thereby
reduces hepcidin expression [102,106–108]. Supplementing healthy adults with vitamin D decreased
hepcidin levels by 73% [109] and significantly increased haemoglobin levels in critically ill patients
following administration of up to 100,000 IU of vitamin D daily for 5 days [107]. These recent results
highlight the importance of vitamin D in the context of anaemia (Figure 2).
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Dietary vitamin C enhances iron absorption by providing reducing equivalents for Fe3+ reduction
by the enzyme ferric reductase to enhance its activity. Vitamin C also suppresses the inhibitory features
of phytate and calcium on iron uptake. Vitamin D obtained from the diet or generated i the skin
through ultraviolet-induced photolysis of vitamin D precursors ugments iron absorption by lowering
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Recently, new orally available products have been introduced into clinical practice. One of these,
ferric maltol, has been successfully studied in a phase III trial in IBD patients with iron-deficiency
anaemia who had previously been either intolerant or unresponsive to oral ferrous products [110].
Although the optimal dose of oral iron supplements in patients with IBD and iron deficiency has
not been established, a dose of 50–200 mg/day of elemental iron is often recommended [111]. Only
10–25% of the dosed iron is expected to be absorbed in iron-deficient patients [71,97]. Because oral iron
induces the expression of hepcidin, it appears reasonable to dose oral iron only once daily to circumvent
the inhibitory effects of hepcidin on iron transfer from duodenal enterocytes to the circulation. A recent
observational trial confirmed this notion. It was shown that oral administration of iron reduced the
level of iron absorption on the following day and that application of iron twice daily resulted in a
significant reduction in oral iron bioavailability. Of note, the relative percentage of absorbed iron could
be increased even by administration every second day [112]. This observation, combined with a very
recent study in women with depleted iron stores demonstrating that alternate-day administration of
oral iron supplementation resulted in higher fractional as well as total iron absorption compared with
daily administration [113], may alter the current practice of oral iron administration.
Given the low absorption of oral iron, a high proportion remains in the gut and is associated with
the development of gastrointestinal side effects, including nausea, dyspepsia, diarrhoea, abdominal
discomfort, vomiting and constipation in up to 20% of patients—often resulting in nonadherence to
therapy [26,114]. Generally, nausea and abdominal discomfort occur within 1–2 h of drug intake and
appear to be dose related, whereas other gastrointestinal side effects such as diarrhoea and constipation
are idiosyncratic [71,111]. In patients reporting such intolerances, a delayed-release enteric-coated
iron tablet may be prescribed. However, the bioavailability of iron from these formulations is reduced
compared with standard preparations because almost all the iron is absorbed in the duodenum and
not in distal part of the gastrointestinal tract [45,47]. Moreover, because oral iron is poorly absorbed in
the setting of ongoing inflammation [21], IBD patients with increased C-reactive protein (CRP) levels
often show a diminished response to oral iron therapy [115].
Most of the reservations regarding oral iron therapy in IBD come from studies in animal models,
which have shown contradictory evidence regarding the impact of oral iron on ongoing intestinal
inflammation [35,116]. In humans, the clinical evidence for the effects of oral iron in patients with
flaring IBD is also controversial [38,117]. It is, however, established that iron therapy significantly
affects the composition of the microbiome [118,119]. This is of interest because the composition of the
microbiome is regarded as an important factor in the pathogenesis of IBD [120]. A recent open-label
clinical trial showed a significant impact of iron supplementation (both oral and intravenous) on the
phylogenetic composition and faecal metabolite landscape in patients with IBD and iron deficiency
or anaemia [118]. A difference between the impact of orally and intravenously administered iron on
bacterial phylotypes and faecal metabolites seems to exist and this may relate to differences in iron
pharmacokinetics and iron availability for gut bacteria. Moreover, patients with CD appear to be more
prone to changes in microbiome composition following iron replacement therapy and intravenous iron
therapy might in fact benefit such anaemic patients with an unstable microbiota [118]. Based on these
findings, iron ingestion may potentially influence the disease course in patients with IBD [118,121].
5.2. Intravenous Regimen
Parenteral iron administration more rapidly increases haemoglobin levels than oral delivery [122,123]
and this option traditionally has been reserved for patients who are intolerant to or respond
inadequately to oral iron supplementation, as well as for patients in whom a rapid iron replenishment
is desired (e.g., patients scheduled for surgery) [25,85,114]. This approach is reflected by the
indications approved by the U.S. Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) for a number of intravenous iron preparations [124,125]. In the past, when
high-molecular-weight dextrans were used for intravenous iron therapy, infrequent severe or
life-threatening anaphylactic reactions were reported following intravenous administration [126].
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However, the risk of these severe adverse events is lower today with the currently used preparations
including high-molecular-weight iron components [127]. Compared with oral administration,
intravenous iron increases haemoglobin levels and iron storage and improves quality of life more
rapidly but not always more effectively [119,128,129]. The disadvantages—apart from a higher cost
of therapy—include a risk of infusion-related anaphylaxis, which means that equipment to manage
such potentially life-threatening situations must be in place [127]. Moreover, intravenous iron has been
recommended in favour of oral iron therapy in patients with more advanced inflammation to bypass
the blockade of iron absorption by hepcidin, although clinical data are scarce in proof of concept of
this suggestion. Patients with more advanced inflammation/severe disease activity have often been
excluded from prospective clinical trials evaluating the efficacy of intravenous iron in IBD. Of note,
a retrospective analysis of results from various clinical trials suggested that pre-treatment CRP levels
are not significantly associated with therapeutic responses to intravenous iron [115].
Six intravenous iron preparations are available at present. These include iron dextran, iron
gluconate and iron sucrose, as well as the more recently licensed high-molecular-weight compounds
ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose [26,130,131]. The structural stability of
these high-dose preparations is high and allows only the release of a low level of labile iron into the
circulation, resulting in improved safety profiles and infusion of higher iron dosages. In most patients,
the total iron dose required therefore can be provided in a single infusion.
5.2.1. Low-Molecular-Weight Iron
The iron dextran compounds exist in two forms that are stable: A low- (73 kDa) and a
high-molecular-weight (165 kDa) complex. Because the latter has been linked to an increased risk of
both anaphylactic and anaphylactoid reactions [132–135], only the low-molecular-weight iron dextran
is currently marketed in Europe [136]. This form can be administered as a single dose of up to 200 mg
over a minimum infusion period of 30 min [137]. Previously it was recommended first to administer a
test dose to check for the risk of anaphylactic reactions (i.e., 0.5 mL over 2–5 min) before providing the
full dose but this precaution is no longer recommended by the EMA [124].
The stability of both iron gluconate (37 kDa) and iron sucrose (43 kDa) is lower than that of iron
dextran and these two iron compounds can be administrated at a maximal single dose of 200 mg of
iron gluconate (300 mg in some countries) over a minimum infusion time of 30 min [138] or 62.5 mg of
iron sucrose (125 mg in some countries) over an infusion time of 5–10 min [139] without requiring a
test dose. Increasing the dosages [140] or the infusion rates [53] enhances the risk of adverse events
such as transient hypotension due to the release of labile iron. Accordingly, iron dextran, iron sucrose
and iron gluconate preparations usually will require multiple rounds of administration with lower
doses to replenish iron stores.
5.2.2. High-Molecular-Weight Iron Compounds
The introduction of more stable iron complex formulations for intravenous iron administration
has permitted the infusion of higher single doses with minimal side effects and no need for test
doses because of the marginal release of labile iron during administration. The highly stable 150 kDa
complexes ferric carboxymaltose [141–145] and iron isomaltoside 1000 [146,147] allow for controlled
and safe delivery of higher doses of molecular iron per infusion. Ferric carboxymaltose may be
administered effectively at a dose up to 1000 mg over a period of at least 15 min once per week [146].
Iron isomaltoside 1000, because of its stable structure, can be administrated in single doses of up to 20
mg/kg of body weight within a period of 15 min [146]. Currently, limited data exist on iron isomaltoside
1000 for the treatment of iron-deficiency anaemia in patients with IBD [129,147], although clinical trials
are currently ongoing. Ferumoxytol has a molecular weight of 721 kDa, which allows for rapid dosing
of relatively large doses [148]. A recent phase III randomized, double-blind, placebo-controlled trial
conducted at 182 sites in the United States, India and Europe evaluated administration of 510 mg doses
of ferumoxytol followed by a second dose 2–8 days later in 231 patients with various gastrointestinal
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conditions (including IBD, polyps and colon cancer). In this study, ferumoxytol was efficacious and
generally well tolerated in patients with iron-deficiency anaemia along with underlying gastrointestinal
disorders who had a history of unsatisfactory oral iron supplementation [149]. However, with respect
to IBD, it has been suggested that the paramagnetic nature of ferumoxytol might lead to interference
during magnetic resonance imaging (MRI) examinations [150] and such interference might hamper its
use in a subset of IBD patients because MRI examinations are an important diagnostic tool in their
management. Further, a comparison of different intravenous iron products in the United States showed
that ferumoxytol, per sold unit, had the highest rate of adverse events [151], impeding its benefit-risk
ratio. In addition, since March 2015, a boxed warning by the FDA has been attached to this product
regarding potentially life-threatening allergic reactions.
Although different side-effect profiles are associated with various preparations of large-molecule
iron complexes [133], the most frequently reported complaints after infusion are itching, dyspnea,
wheezing and myalgia [152]. Moreover, it should be noted that acute myalgia following a first
intravenous iron administration (without any other symptoms) ceases spontaneously within minutes
(i.e., the so-called Fishbane reaction) and does not recur at re-challenge [152,153]. In addition, more
specific side effects include hypotension, tachycardia, dyspepsia, diarrhoea, stridor, nausea, skin
flushing and periorbital oedema. Serious side effects are rare following intravenous iron infusion [154]
but can include cardiac arrest [155]. The risk is increased among elderly patients and has been observed
most often following infusion of high-molecular-weight dextran-containing preparations that are no
longer in clinical use [156]. Accordingly, an initial low infusion rate is advisable, as well as a close
monitoring of patients for signs of hypersensitivity both during administration of an intravenous iron
formulation and for at least 30 min thereafter [124].
Based on our expanding knowledge of the pathways underlying inflammatory anaemia and
specifically the role of hepcidin, new therapeutic strategies are emerging that attempt to block hepcidin
activity either by directly interfering with hepcidin synthesis by affecting different inflammation- or
iron-driven signalling pathways that regulate hepcidin expression (such as SMAD, STAT3, BMP, BMPR,
or TMPRSS6) or by neutralizing hepcidin in the circulation [57,157–160] (Figure 1). Such interventions
are currently under clinical investigation but they can only be effective in patients with inflammation-
or renal insufficiency- driven hepcidin elevation and subsequent iron retention in macrophages, where
hepcidin antagonization will result in redistribution of iron to the circulation and delivery of the metal
to erythroid progenitors. In patients with true iron deficiency in the setting of inflammation, which is
often the case in IBD, such therapies will not work and iron supplementation will remain the treatment
of choice. Another set of new drugs has arisen from the development of prolyl-hydroxylase inhibitors.
These therapeutic agents cause stabilization of HIFs, resulting in increased endogenous erythropoietin
formation and stimulation of iron uptake based on the regulatory effects of HIFs on the expression
of transmembrane iron transporters. These agents are currently being investigated in clinical trials
mainly to combat renal anaemia [161–163].
6. Evidence of Management
Members of our group previously performed a systematic search that yielded a total of 632
studies concerning iron therapy in IBD published from January 2004 to March 2015 (i.e., in a time
frame with novel high-dose intravenous iron preparations), of which 13 prospective trials met the
inclusion criteria as randomized, controlled trials and included 2906 patients in total [164]. This
systematic review indicated that administration of intravenous iron in IBD patients with mild anaemia
(haemoglobin ≥ 10 g/dL) frequently resulted in higher ferritin levels but not in higher haemoglobin
concentrations compared with oral iron supplementation at short-term follow-up [129,144,145,165].
In more aggravated iron-deficiency anaemia, intravenous iron supplementation was superior to oral
treatment when the evaluation was based on the increase in haemoglobin [128,134,145,165].
Comparative studies of intravenous versus oral iron supplementation in the systematic review
did not demonstrate any significant difference in haemoglobin normalization favouring the use of
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intravenous iron therapy unless considered for patients with intolerance or an inadequate response to
oral supplementation [164]. In patients undergoing biological therapy with TNF inhibitors, concomitant
iron supplementation may be prescribed without affecting the disease course/activity. Moreover,
another recent systematic review of randomized, controlled trials with the aim of assessing drug safety
demonstrated that intravenous iron therapy may increase the risk of infection [166]. This issue has
also been evaluated in predialysis and dialysis patients indicating differences in the risk of infection
based on baseline ferritin levels, mode of administration (intermittent or bolus) and the specific drugs
used [167–171].
It is known that apart from the WHO definitions of anaemia [31], a low TfS in fasting blood
samples (<20%) and a serum ferritin concentration of less than 30 µg/L (with a serum CRP level within
the normal range or a ferritin concentration of less than 100 µg/L with an elevated serum CRP level)
are suitable laboratory tests for the diagnosis and assessment of iron deficiency in IBD used in the
randomized, controlled studies [164].
Only nine randomized, controlled trials investigating oral iron supplementation in IBD patients
were published between 2004 and 2017 [35,110,128,129,134,138,144,145,165]. Oral supplementation
appears to be well tolerated and has a positive effect on both haemoglobin levels and body iron
parameters. From these studies, it seems that milder side effects (i.e., abdominal discomfort,
diarrhoea, nausea and vomiting) occur less often after intravenous therapy than after oral
therapy [128,134,138,144,165], although one study did not report any differences [129]. No comparison
of side effects based on the various forms of oral supplementation was, however, performed. From
an examination of the available data, it was apparent that there are no indications that oral iron
supplementation exacerbates symptoms of the underlying IBD. Only one study in this systematic
review [164] reported worsening of disease activity in 2 of 33 patients with UC (but not in patients with
CD). However, in this study, the IBD quality-of-life scores improved significantly (p = 0.016) at the same
time [35] and when the eight studies using oral iron supplementation were evaluated, it was apparent
that an adequate level of evidence is provided to verify the safety of oral iron supplementation in IBD.
Of note, a study with oral ferric maltol has suggested that this drug may be an alternative for patients
who are unresponsive to or intolerant of formulations containing ferrous salts [110], an observation
that needs to be confirmed in future studies, though.
A very recent systematic review and Bayesian network meta-analysis performed on the five
eligible randomized, controlled trials with a total population of 1143 patients has shown ferric
carboxymaltose to be the most effective preparation for the treatment of iron-deficiency anaemia
in IBD, followed by iron sucrose, iron isomaltoside and oral iron in fourth place [172]. This analysis
incorporated all currently available evidence on intravenous iron replacements in IBD patients with
iron-deficiency anaemia and is the first attempt to systematically and quantitatively review the
literature in the field.
It is generally accepted that individuals with iron deficiency and coexisting anaemia need
treatment. It is, however, a subject of debate whether treatment of iron deficiency should be initiated
before the development of anaemia—a condition that recently was reported to occur in 37% of IBD
patients in a Spanish outpatient cohort [173]—because data from clinical trials on this issue are scarce.
Thus, a placebo-controlled, double-blinded, randomized study in women with iron deficiency but
without anaemia indicated that intravenous iron administration resulted in an improvement of fatigue
in 82% of patients in the intervention group compared with 47% in the placebo group and that the
effect of iron supplementation on fatigue was most pronounced in women with an initial ferritin
concentration of less than 15 ng/mL [174]. Similar beneficial effects of intravenous iron administration
regarding quality of life in non-anaemic patients with IBD have recently been published [175,176]. Thus,
none of these observational, single centre studies included a placebo control given the high incidence of
placebo mediated benefits on quality of life in such patient cohorts [174,177]. Nevertheless, it has to be
kept in mind that uncritical iron supplementation or iron overloading may have several adverse effects
described herein, including allergic reactions, risk of infections or intravascular oxidative stress as well
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as impairment of mitochondrial function with subsequent fatigue [178]. This leads to the yet unsolved
question of therapeutic start and end points in terms of target haemoglobin and/or sTfS/ferritin levels
and whether or not full correction of anaemia is optimal for patients with inflammation-associated
anaemia. Nevertheless, patients with concomitant diseases such as congestive heart failure and fatigue
due to true iron deficiency may benefit from such iron supplementation [70].
7. Recommendations for Clinicians
The cause of anaemia and specifically of concomitant iron deficiency should be identified in
every patient with IBD. Thus, the recurrence of iron deficiency following successful treatment is often
due to persistence or relapse of the initial inciting cause (e.g., recurrent gastrointestinal or urogenital
bleeding), which should be managed appropriately. Further, in patients who have failed to respond to
either oral or parenteral iron therapy, the cause for this failure should be carefully determined.
Previously it was accepted that clinical symptoms of anaemia occurred only when the
haemoglobin level dropped abruptly [37] and, conversely, that patients would adapt to low
haemoglobin levels if the anaemia developed slowly. This led to the concept of asymptomatic anaemia.
In truth, the term asymptomatic seems to reflect the fact that impairments in physical condition,
quality of life, cardiovascular performance and cognitive function may have been neglected by both
patients and their physicians. Therefore, the process of adaptation in chronic anaemia seems to be
an acceptance/toleration of impaired quality of life [37] and chronic fatigue and reduced physical
activity/cardiovascular performance caused by anaemia may actually debilitate and even worry
patients with IBD as much as abdominal pain or diarrhoea [37]. Accordingly, the beneficial effect on
quality of life and metabolic processes derived from the correction of anaemia in patients with IBD
may be just as important as the control of their intestinal disease [37].
7.1. Oral versus Intravenous Iron Supplementation
Clinical guidelines often emphasize that because of the ease of treatment, patients with
uncomplicated iron-deficiency anaemia should be treated with oral rather than intravenous iron
formulations [179]. In this context, an appropriate dosage for treatment of iron deficiency in adults
is usually recommended in the range of 100–200 mg/day of elemental iron but guidelines do not
consider that a number of side effects are dose related and might be prevented by reducing the dosage
to as low as 50 mg of elemental iron per day in selected patients, which, in fact, may be sufficient to
correct mild iron-deficiency anaemia [180].
Indications for intravenous iron administration include severe anaemia (haemoglobin < 10 g/dL),
intolerance of or inappropriate response to oral iron administration, severe intestinal disease activity
and concomitant therapy with an erythropoiesis agent or patient preference. Oral iron supplements
can be used if these indications for intravenous therapy are not met.
If intravenous iron supplementation is considered, the use of low-dose regimens is not
recommended from the point of view of clinical efficacy because a number of infusions might be
needed over several days or weeks. Instead, high-dose regimens that result in fewer infusions and
increase both convenience and cost-effectiveness of intravenous iron repletion should be considered.
The optimal dosing strategy for intravenous iron compounds depends on the type of preparation,
the body weight of the patient and the haemoglobin concentration. The amount of iron needed to
correct the haemoglobin can be calculated using the Ganzoni equation [181], often regarded as the
gold standard, although this formula might underestimate the iron needed when a target haemoglobin
of 13 g/dL and stored iron of 500 mg are used to determine individual iron deficits [129]. Because this
formula is inconvenient in clinical practice [129,144], simpler schemes for the estimation of total iron
need have been published [38,182], including a simple regimen to predict individual iron requirements
for ferric carboxymaltose [142] that may also be used in clinical practice for dosing of other intravenous
iron preparations [38]. It should be mentioned that patients with iron-deficiency anaemia who are
unresponsive even to intravenous iron supplementation (i.e., haemoglobin increase ≤ 2 g/dL within
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4 weeks) may in addition need recombinant erythropoiesis-stimulating agents after ruling out other
causes of anaemia such as vitamin deficiencies [183–185].
7.2. Surveillance of Patients Following Iron Supplementation
Last but not least, it should be kept in mind that iron deficiency in IBD often relapses after
iron replenishment [143]. Consequently, periodic monitoring, for example, every 3 months during
treatment and again after a year once the haemoglobin value is normalized and iron stores are
replenished (i.e., preventive treatment), is essential to assess whether retreatment is required [73]. Such
a proactive concept of anaemia management not only could improve the quality of life for patients
with IBD but also could be of economic benefit. However, we lack solid data on when to stop iron
supplementation therapy in order to avoid iron overloading, which may cause side effects due to
iron-catalysed formation of toxic radicals [31]. Recent guidelines on the management of anaemia
among dialysis patients suggest that ferritin levels of up to 500 ng/mL appear to be safe and this also
might be a useful upper threshold in the management of patients with IBD and anaemia [186].
This leads to the questions of (1) therapeutic start and end points (i.e., when should iron
supplementation therapy be initiated and when it should be discontinued?) and (2) whether or
not iron-deficiency anaemia should be treated differently depending on the underlying disease?
To start with the latter point, in general, subjects with pure iron-deficiency anaemia on the basis of an
inadequate dietary iron intake and/or increased blood losses and iron-deficient IBD patients with no or
minimal signs of inflammation should initially be recommended to oral iron therapy. However, such a
recommendation might have some caveats. Oral iron replacement therapy may be of limited efficiency
in the setting of concomitant inflammation, which is usually associated with increased hepcidin
concentrations resulting in an impaired response to iron therapy [84,187]. Yet true iron deficiency in
the setting of inflammation causes hepcidin reduction and enables duodenal iron absorption, although
to a lesser extent than in healthy control individuals [21,62,63]. Second, iron supplementation may be
a problem in areas with an endemic burden of infectious disease or in patients with active infections
because iron is an essential growth factor for many microbes and also has an impact on antimicrobial
immune responses [188]. Thus, dietary iron fortification strategies were associated with an increased
risk of infections such as malaria, bacterial meningitis, bacterial pneumonia and viral diarrhoea along
with a rise in infection-related mortality [189,190].
7.3. General Precautions for Iron Supplementation
While normalization of haemoglobin appears to be a reasonable readout in subjects with
iron-deficiency anaemia in the absence of inflammation [31], retrospective data, mainly from patients
with chronic kidney disease, who are also characterized by a low-grade inflammation, indicate that
haemoglobin normalization seems to be associated with an increased mortality compared with subjects
with mild anaemia [28,191,192]. This has resulted in recommendations from different societies that
in the presence of an inflammatory disease, including cancer or autoimmune disorders, the target
haemoglobin concentration should be slightly below normal [28,31]. However, this is an extrapolation
of data from observational studies and it is still unknown whether this is also true for patients with IBD.
Importantly, life-threatening reactions possibly caused by release of free iron are rare
after administration of intravenous iron supplementation therapies [127,193]. Thus, practical
recommendations for minimizing the risk of hypersensitivity reactions, for example, by assessing
any previous adverse reactions, multiple drug allergies, or severe atopy, should be applied. Also,
decreasing the infusion rate as well as maintaining an appropriately staffed site equipped with
resuscitation facilities may be considered [127]. An incompletely understood issue is the development
of hypophosphatemia in some patients specifically in association with ferric-carboxymaltose
administration. Infrequently, hypophosphatemia may become severe and life threatening and may
be linked to alterations of the FWF23 and vitamin D pathways, although the details of that network,
as well as measures to identify patients at risk, are not available thus far [194].
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Patients with inflammatory diseases will respond poorly to oral iron therapy unless the iron
deficiency is severe. Newer iron formulations, such as ferric maltose, have been shown to correct mild
anaemia in patients with quiescent IBD [110] but whether this is also true in flaring IBD still remains
to be established. Nevertheless, in patients with inflammation and anaemia based on iron-limited
erythropoiesis and in patients with non-inflammatory-driven severe iron-deficiency anaemia, in whom
a fast recovery of depleted iron stores is desired, intravenous iron appears to be the treatment of choice.
Still, the evidence from studies in proof of this latter concept is rather scare [179] and we still lack
data from prospective trials on the efficacy of intravenous iron preparations in patients with more
advanced inflammation.
8. Conclusions
Here we have summarized the impact and pathophysiology of iron deficiency in the setting
of IBD. Diagnostic criteria are provided as well as methods to differentiate between functional and
true iron deficiency. We also discussed the currently available drugs and commented on issues that
should be considered by physicians treating patients with IBD. Thus, treating physicians need to pay
more attention to the management of anaemia and iron deficiency for improvement of the general
well-being of their patients with IBD—a matter that actually does not gain the attention it deserves.
Although we lack knowledge on the effects of iron repletion strategies on the course of IBD, the control
of inflammation is pivotal in the management of anaemia in this intestinal disorder.
Given the novel intravenous high-dose iron replacement regimens introduced within the last
decade, oral iron therapy should be preferred for IBD patients with mild and uncomplicated
iron-deficiency anaemia (haemoglobin ≥ 10 g/dL) in quiescent disease stages unless previous
complications have been observed, including an inadequate response (haemoglobin increase < 2 g/dL
within 4 weeks) [195]. Intravenous iron supplementation may be of advantage in patients with
aggravated iron-deficiency anaemia or flaring IBD (haemoglobin < 10 g/dL) because inflammation
hampers intestinal iron absorption [27,196,197]. Further, based on the available data, iron therapy
can be administered concomitantly with TNF inhibitors [198], a class of drugs widely used in the
management of IBD [199]. When using intravenous iron preparations, physicians must be aware of
infusion-related side effects and the risk of hypophosphatemia. Further, efficacy studies of intravenous
iron preparations in patients with more advanced inflammation are urgently desired.
Finally, it should be emphasized that iron deficiency may relapse often after iron
replenishment [143], specifically when IBD activity is not well controlled and consequently, periodic
monitoring should be highlighted to assess whether retreatment is required [73]. However, we still
lack solid data on when to stop iron supplementation therapy in order to avoid side effects due to
iron overloading. Thus large, well-designed collaborative prospective trials involving scientists and
physicians from different disciplines are warranted to assess the true impact on the management of
IBD associated with iron-deficiency anaemia.
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